Epigenetic regulation in heart failure

Current Opinion in Cardiology

Volumn 31, Issue 3, 2016, Pages 255-265

  Kim, Soo Young ^a   Morales, Cyndi R ^a   Gillette, Thomas G ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aging; Epigenetics; Heart failure; Metabolism

Indexed keywords

MITOCHONDRIAL DNA; UNTRANSLATED RNA; CHROMATIN;

ACETYLATION; AGING; CELL ENERGY; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPLEX FORMATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE; HEMODYNAMIC STRESS; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; METABOLISM; MITOCHONDRION; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; CHROMATIN; GENETIC EPIGENESIS;

ACETYLATION; ANIMALS; CHROMATIN; DNA METHYLATION; DNA, MITOCHONDRIAL; EPIGENESIS, GENETIC; HEART FAILURE; HUMANS; RNA, UNTRANSLATED;

EID: 84961896776     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000276     Document Type: Review

References (156)

1. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370-1380.
2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8:30-41.
3. Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A Biol Sci Med Sci 2001; 56:M88-M96.
4. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006; 119:591-599.
5. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-313.
6. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376:875-885.
7. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
8. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006; 98:15-24.
9. Nandi SS, Mishra PK. Harnessing fetal and adult genetic reprograming for therapy of heart disease. J Nat Sci 2015; 1:e71.
10. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004; 109:1580-1589.
11. Duygu B, de Windt LJ, da Costa Martins PA. Targeting microRNAs in heart failure. Trends Cardiovasc Med 2016; 26:99-110.
12. Katz AM. The 'modern' view of heart failure: how did we get here? Circ Heart Fail 2008; 1:63-71.
13. Papait R, Greco C, Kunderfranco P, et al. Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol 2013; 108:361.
14. Di Salvo TG, Haldar SM. Epigenetic mechanisms in heart failure pathogenesis. Circ Heart Fail 2014; 7:850-863.
15. Gillette TG, Hill JA. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res 2015; 116:1245-1253.
16. Han P, Hang CT, Yang J, Chang CP. Chromatin remodeling in cardiovascular development and physiology. Circ Res 2011; 108:378-396.
17. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12:599-606.
18. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 1964; 51:786-794.
19. Khan SN, Khan AU. Role of histone acetylation in cell physiology and diseases: an update. Clin Chim Acta 2010; 411:1401-1411.
20. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Gen 2009; 10:32-42.
21. Yanazume T, Hasegawa K, Morimoto T, et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 2003; 23:3593-3606.
22. Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003; 278:28930-28937.
23. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110:479-488.
24. McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 2012; 52:303-319.
25. Venkatasubramanian S, Noh RM, Daga S, et al. Cardiovascular effects of a novel Sirt1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc 2013; 2:e000042.
26. Houtkooper RH, Auwerx J. Exploring the therapeutic space around NAD+. J Cell Biol 2012; 199:205-209.
27. Spiltoir JI, Stratton MS, Cavasin MA, et al. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol 2013; 63:175-179.
28. Anand P, Brown JD, Lin CY, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013; 154:569-582.
29. Kruidenier L, Chung CW, Cheng Z, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012; 488:404-408.
30. Zhang QJ, Chen HZ, Wang L, et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest 2011; 121:2447-2456.
31. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005; 115:547-555.
32. Nagoshi T, Yoshimura M, Rosano GM, et al. Optimization of cardiac metabolism in heart failure. Curr Pharm Des 2011; 17:3846-3853.
33. Battiprolu PK, Lopez-Crisosto C, Wang ZV, et al. Diabetic cardiomyopathy and metabolic remodeling of the heart. Life Sci 2013; 92:609-615.
34. Sankaralingam S, Lopaschuk GD. Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series). Pulm Circ 2015; 5:15-28.
35. Connaughton S, Chowdhury F, Attia RR, et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol 2010; 315:159-167.
36. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 1997; 29:2771-2778.
37. Wu P, Sato J, Zhao Y, et al. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 1998; 329 (Pt 1):197-201.
38. Mori J, Zhang L, Oudit GY, Lopaschuk GD. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol 2013; 63:98-106.
39. Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 2002; 51:276-283.
40. Battiprolu PK, Hojayev B, Jiang N, et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012; 122:1109-1118.
41. Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 1997; 134 (5 Pt 1):841-855.
42. Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010; 3:420-430.
43. Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 1998; 21:888-892.
44. Matsuhashi T, Hishiki T, Zhou H, et al. Activation of pyruvate dehydrogenase by dichloroacetate has the potential to induce epigenetic remodeling in the heart. J Mol Cell Cardiol 2015; 82:116-124.
45. Cai L, Sutter BM, Li B, Tu BP. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 2011; 42:426-437.
46. Moussaieff A, Rouleau M, Kitsberg D, et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab 2015; 21:392-402.
47. Shi L, Tu BP. Protein acetylation as a means to regulate protein function in tune with metabolic state. Biochem Soc Trans 2014; 42:1037-1042.
48. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008; 10:179-206.
49. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab 2011; 14:528-536.
50. Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 2009; 324:651-654.
51. Ryall JG, Dell'Orso S, Derfoul A, et al. The NAD(+)-dependent Sirt1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells. Cell Stem Cell 2015; 16:171-183.
52. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein SIR2 is a NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
53. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570-2580.
54. Rogina B, Helfand SL. SIR2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A 2004; 101:15998-16003.
55. Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1:3.
56. Cencioni C, Spallotta F, Mai A, et al. Sirtuin function in aging heart and vessels. J Mol Cell Cardiol 2015; 83:55-61.
57. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 2015; 36:3404-3412.
58. Gorenne I, Kumar S, Gray K, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013; 127:386-396.
59. Kawahara TL, Michishita E, Adler AS, et al. Sirt6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009; 136:62-74.
60. Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin Sirt6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med 2012; 18:1643-1650.
61. Tian K, Liu Z, Wang J, et al. Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor kappaB signaling. Transl Res 2015; 165:374-386.
62. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol 2012; 107:273.
63. Hsu CP, Oka S, Shao D, et al. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+synthesis in cardiac myocytes. Circ Res 2009; 105:481-491.
64. Cai Y, Yu SS, Chen SR, et al. NMNAT2 protects cardiomyocytes from hypertrophy via activation of Sirt6. FEBS Lett 2012; 586:866-874.
65. Kamemura K, Ogawa M, Ohkubo S, et al. Depression of mitochondrial metabolism by downregulation of cytoplasmic deacetylase, HDAC6. FEBS Lett 2012; 586:1379-1383.
66. Lemon DD, Horn TR, Cavasin MA, et al. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol 2011; 51:41-50.
67. Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of alpha-tubulin proteostasis in experimental and human atrial fibrillation. Circulation 2014; 129:346-358.
68. Demos-Davies KM, Ferguson BS, Cavasin MA, et al. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol 2014; 307:H252-H258.
69. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013; 339:211-214.
70. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and Sirt1 activity. Nature 2009; 458:1056-1060.
71. Canto C, Jiang LQ, Deshmukh AS, et al. Interdependence of AMPK and Sirt1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010; 11:213-219.
72. Keating ST, El-Osta A. Epigenetics and metabolism. Circ Res 2015; 116:715-736.
73. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13:343-357.
74. Kaneda R, Takada S, Yamashita Y, et al. Genome-wide histone methylation profile for heart failure. Genes Cells 2009; 14:69-77.
75. Papait R, Cattaneo P, Kunderfranco P, et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A 2013; 110:20164-20169.
76. Hohl M, Wagner M, Reil JC, et al. HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 2013; 123:1359-1370.
77. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13:297-311.
78. Stein AB, Jones TA, Herron TJ, et al. Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. J Clin Invest 2011; 121:2641-2650.
79. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007; 8:307-318.
80. Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Krebs cycle intermediates regulate DNA and histone methylation: epigenetic impact on the aging process. Ageing Res Rev 2014; 16:45-65.
81. Ringrose L, Paro R. Polycomb/trithorax response elements and epigenetic memory of cell identity. Development 2007; 134:223-232.
82. Greer EL, Maures TJ, Hauswirth AG, et al. Members of the H3K4 trimethylation complex regulate lifespan in a germline-dependent manner in C. elegans. Nature 2010; 466:383-387.
83. Wang QT. Epigenetic regulation of cardiac development and function by polycomb group and trithorax group proteins. Dev Dyn 2012; 241:1021-1033.
84. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423:302-305.
85. Gonzalez-Valdes I, Hidalgo I, Bujarrabal A, et al. Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence. Nat Commun 2015; 6:6473.
86. Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397:164-168.
87. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25:1010-1022.
88. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Gen 2013; 14:204-220.
89. Sen GL, Reuter JA, Webster DE, et al. DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature 2010; 463:563-567.
90. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases DNMT3A and DNMT3B are essential for de novo methylation and mammalian development. Cell 1999; 99:247-257.
91. Tao H, Yang JJ, Chen ZW, et al. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology 2014; 323:42-50.
92. Gilsbach R, Preissl S, Gruning BA, et al. Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease. Nat Commun 2014; 5:5288.
93. Xiao D, Dasgupta C, Chen M, et al. Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res 2014; 101:373-382.
94. Movassagh M, Choy MK, Knowles DA, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011; 124:2411-2422.
95. Haider S, Cordeddu L, Robinson E, et al. The landscape of DNA repeat elements in human heart failure. Genome Biol 2012; 13:R90.
96. Haas J, Frese KS, Park YJ, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 2013; 5:413-429.
97. Movassagh M, Choy MK, Goddard M, et al. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE 2010; 5:e8564.
98. Connelly JJ, Cherepanova OA, Doss JF, et al. Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis. Hum Mol Genet 2013; 22:5107-5120.
99. Castegna A, Iacobazzi V, Infantino V. The mitochondrial side of epigenetics. Physiol Genomics 2015; 47:299-307.
100. Wallace DC. The epigenome and the mitochondrion: bioenergetics and the environment [corrected]. Genes Dev 2010; 24:1571-1573.
101. Koczor CA, Jiao Z, Fields E, et al. AZT-induced mitochondrial toxicity: an epigenetic paradigm for dysregulation of gene expression through mitochondrial oxidative stress. Physiol Genomics 2015; 47:447-454.
102. Dorn GW 2nd, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev 2015; 29:1981-1991.
103. van der Wijst MG, Rots MG. Mitochondrial epigenetics: an overlooked layer of regulation? Trends Genet 2015; 31:353-356.
104. Ghosh S, Sengupta S, Scaria V. Comparative analysis of human mitochondrial methylomes shows distinct patterns of epigenetic regulation in mitochondria. Mitochondrion 2014; 18:58-62.
105. Shock LS, Thakkar PV, Peterson EJ, et al. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc Natl Acad Sci U S A 2011; 108:3630-3635.
106. Wong M, Gertz B, Chestnut BA, Martin LJ. Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. Front Cell Neurosci 2013; 7:279.
107. Ngo HB, Kaiser JT, Chan DC. The mitochondrial transcription and packaging factor tfam imposes a u-turn on mitochondrial DNA. Nat Struct Mol Biol 2011; 18:1290-1296.
108. Ikeda M, Ide T, Fujino T, et al. Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS ONE 2015; 10:e0119687.
109. Baccarelli AA, Byun HM. Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease. Clin Epigenetics 2015; 7:44.
110. Akkerman JW. Regulation of carbohydrate metabolism in platelets. A review. Thromb Haemost 1978; 39:712-724.
111. Elia L, Condorelli G. RNA (epi)genetics in cardiovascular diseases. J Mol Cell Cardiol 2015; 89:11-16.
112. Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31:367-373.
113. Greco S, Gorospe M, Martelli F. Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol 2015; 83:142-155.
114. Das S, Bedja D, Campbell N, et al. miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS ONE 2014; 9:e96820.
115. Wang H, Li J, Chi H, et al. microRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells. J Cell Mol Med 2015; 19:2084-2097.
116. Zhou J, Gao J, Zhang X, et al. microRNA-340-5p functions downstream of cardiotrophin-1 to regulate cardiac eccentric hypertrophy and heart failure via target gene dystrophin. Int Heart J 2015; 56:454-458.
117. Zhu X, Wang H, Liu F, et al. Identification of micro-RNA networks in endstage heart failure because of dilated cardiomyopathy. J Cell Mol Med 2013; 17:1173-1187.
118. DuanQ, Yang L, Gong W, et al. microRNA-214 is upregulated in heart failure patients and suppresses XBP1-mediated endothelial cells angiogenesis. J Cell Physiol 2015; 230:1964-1973.
119. el Azzouzi H, Leptidis S, Dirkx E, et al. The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell Metab 2013; 18:341-354.
120. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012; 3:1078.
121. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124:1537-1547.
122. Goretti E, Wagner DR, Devaux Y. miRNAs as biomarkers of myocardial infarction: a step forward towards personalized medicine? Trends Mol Med 2014; 20:716-725.
123. Muthusamy S, DeMartino AM, Watson LJ, et al. microRNA-539 is upregulated in failing heart, and suppresses O-GlcNAcase expression. J Biol Chem 2014; 289:29665-29676.
124. Su M, Wang J, Wang C, et al. microRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ 2015; 22:986-999.
125. Bernardo BC, Gao XM, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 2012; 109:17615-17620.
126. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013; 495:107-110.
127. Choi SE, Fu T, Seok S, et al. Elevated microRNA-34a in obesity reduces NAD+ levels and Sirt1 activity by directly targeting NAMPT. Aging Cell 2013; 12:1062-1072.
128. da Costa Martins PA, Salic K, Gladka MM, et al. microRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010; 12:1220-1227.
129. Greco S, Fasanaro P, Castelvecchio S, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012; 61:1633-1641.
130. Zheng D, Ma J, Yu Y, et al. Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia 2015; 58:1949-1958.
131. Kuwabara Y, Horie T, Baba O, et al. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res 2015; 116:279-288.
132. Arnold N, Koppula PR, Gul R, et al. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One 2014; 9:e103284.
133. Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2014; 63:920-927.
134. Talasila A, Yu H, Ackers-Johnson M, et al. Myocardin regulates vascular response to injury through miR-24/-29a and platelet-derived growth factor receptor-beta. Arterioscler Thromb Vasc Biol 2013; 33:2355-2365.
135. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105:13027-13032.
136. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104:170-178.
137. Potus F, Ruffenach G, Dahou A, et al. Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 2015; 132:932-943.
138. Dirkx E, Gladka MM, Philippen LE, et al. NFAT and miR-25 cooperate to reactivate the transcription factor HAND2 in heart failure. Nat Cell Biol 2013; 15:1282-1293.
139. Wahlquist C, Jeong D, Rojas-Munoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014; 508:531-535.
140. Care A, Catalucci D, Felicetti F, et al. microRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13:613-618.
141. Chen S, Puthanveetil P, Feng B, et al. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 2014; 18:415-421.
142. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008; 22:3242-3254.
143. Sang HQ, Jiang ZM, Zhao QP, Xin F. microRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats. Biomed Pharmacother 2015; 71:185-189.
144. Ikeda S, He A, Kong SW, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009; 29:2193-2204.
145. Tritsch E, Mallat Y, Lefebvre F, et al. An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc Res 2013; 98:372-380.
146. Lai KB, Sanderson JE, Izzat MB, Yu CM. micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int J Cardiol 2015; 199:79-83.
147. Cakmak HA, Coskunpinar E, Ikitimur B, et al. The prognostic value of circulating microRNAs in heart failure: preliminary results from a genomewide expression study. J Cardiovasc Med 2015; 16:431-437.
148. Thome JG, Mendoza MR, Cheuiche AV, et al. Circulating microRNAs in obese and lean heart failure patients: a case-control study with computational target prediction analysis. Gene 2015; 574:1-10.
149. Zhang X, Azhar G, Wei JY. The expression of microRNA and microRNA clusters in the aging heart. PLoS One 2012; 7:e34688.
150. Xu T, Liu Q, Yao J, et al. Circulating microRNAs in response to exercise. Scand J Med Sci Sports 2015; 25:e149-e154.
151. Ellis KL, Cameron VA, Troughton RW, et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15:1138-1147.
152. Nair N, Gupta S, Collier IX, et al. Can microRNAs emerge as biomarkers in distinguishing HFPEF versus HFREF? Int J Cardiol 2014; 175:395-399.
153. Watson CJ, Gupta SK, O'Connell E, et al. microRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17:405-415.
154. Wong LL, Armugam A, Sepramaniam S, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17:393-404.
155. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16:9-17.
156. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013; 153:56-69.